Daniel Dornbusch is the founder of Excision BioTherapeutics. Excision BioTherapeutics has raised $71M in total funding. Latest round: Series A.
Daniel Dornbusch is a co-founder of Excision BioTherapeutics, a biotechnology company based in Philadelphia, Pennsylvania. Founded in 2015, the company develops CRISPR-based gene editing therapies to eliminate chronic viral infections such as HIV, herpes, and hepatitis B. Excision BioTherapeutics secured $60 million in funding in 2021 to advance its HIV clinical trials, with support from investors including Artis Ventures. The company's underlying technology originated from research at Temple University.
Full founder directory · Investor directory · Company funding database · Fundraising library